iTeos Belgium SA
- Country
- π§πͺBelgium
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
- Conditions
- Selected Advanced Solid Tumors
- Interventions
- Drug: EOS006215Drug: Anticancer agent
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 94
- Registration Number
- NCT06877533
- Locations
- πΊπΈ
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈSCRI Oncology Partners, Nashville, Tennessee, United States
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
- Conditions
- Locally Advanced NSCLC - Non-Small Cell Lung CancerMetastatic NSCLC - Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 186
- Registration Number
- NCT05403385
- Locations
- πΊπΈ
Highlands Oncology Group, Fayetteville, Arkansas, United States
πΊπΈInnovative Clinical Research Institute (ICRI), Whittier, California, United States
πΊπΈMid-Florida Hematology & Oncology Centers, PA, Orange City, Florida, United States
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 16
- Registration Number
- NCT05289492
- Locations
- πΊπΈ
Fred Hutchinson Cancer Center, Seattle, Washington, United States
πΊπΈEastern Connecticut Hematology & Oncology, Norwich, Connecticut, United States
π§πͺZNA Cadix, Antwerp, Belgium
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
- Conditions
- Head and Neck CancerAdvanced CancerLung CancerMelanoma
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 153
- Registration Number
- NCT05060432
- Locations
- π§πͺ
Cliniques universitaires St Luc-UCL, Brussels, Belgium
π§πͺJessa Ziekenhuis, Hasselt, Belgium
π§πͺUZ Leuven, Leuven, Belgium
First-In-Human Study of EOS884448 in Participants With Advanced Cancers.
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- iTeos Belgium SA
- Target Recruit Count
- 40
- Registration Number
- NCT04335253
- Locations
- π§πͺ
Universitair Ziekenhuis Gent, Gent, Belgium
π§πͺCliniques universitaires St Luc-UCL, Brussels, Belgium
π§πͺGZA Ziekenhuizen campus Sint-Augustinus, Antwerp, Belgium